1. Home
  2. GNSS vs MGNX Comparison

GNSS vs MGNX Comparison

Compare GNSS & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genasys Inc.

GNSS

Genasys Inc.

HOLD

Current Price

$1.95

Market Cap

101.7M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.92

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNSS
MGNX
Founded
1992
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.7M
115.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
GNSS
MGNX
Price
$1.95
$1.92
Analyst Decision
Strong Buy
Hold
Analyst Count
1
5
Target Price
$5.25
$3.20
AVG Volume (30 Days)
180.7K
562.4K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
44.44
N/A
EPS
N/A
N/A
Revenue
$26,306,790.00
$149,962,000.00
Revenue This Year
$78.94
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.50
155.26
52 Week Low
$1.46
$0.99
52 Week High
$2.89
$2.56

Technical Indicators

Market Signals
Indicator
GNSS
MGNX
Relative Strength Index (RSI) 39.25 65.00
Support Level $1.52 $1.61
Resistance Level $2.38 $1.97
Average True Range (ATR) 0.13 0.09
MACD -0.00 0.01
Stochastic Oscillator 21.43 100.00

Price Performance

Historical Comparison
GNSS
MGNX

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: